US Patent 11129874 Nucleic acids encoding FGF21-Fc fusion proteins
Patent 11129874 was granted and assigned to Novartis on September, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 4 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+310 characters)
Article
Patent abstract
The invention relates to nucleic acids encoding fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are vectors and host cells comprising the same and methods of producing the fusion proteins.
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111298740
Date of Patent
September 28, 2021
0Patent Application Number
201808300
Date Filed
August 30, 2018
0Official Website
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111298740
Date of Patent
September 28, 2021
0Patent Application Number
201808300
Date Filed
August 30, 2018
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 5 Oct, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11129874 Nucleic acids encoding FGF21-Fc fusion proteins
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11129874
Date of patent
September 28, 2021
Patent application number
20180830
Date Filed
August 30, 2018
Find more entities like US Patent 11129874 Nucleic acids encoding FGF21-Fc fusion proteins
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
